| Life-Science Firms Await Funding Details Small life-sciences companies in the U.S. will soon get details, expected to emerge in the next few days, of a federal program that will give a $1 billion boost to the industry. online.wsj.com |
Quest Diagnostics Reports Second Quarter 2010 Financial Results; Updates Guidance for 2010 (PR Newswire) Quest Diagnostics Incorporated , the world's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2010, income from continuing operations increased to $195 million, or $1.07 per diluted share, compared to $188 million, or $1.00 per diluted share, in the second quarter of 2009. us.rd.yahoo.com |
FDA, Clinical Trial Binary Events: Amarin, Amicus, Labopharm Mike Havrilla submits:Below are some Regulatory Catalyst Index updates for companies with recent FDA and clinical trial related news... Amarin Corp. (NASDAQ:AMRN) has a conference call scheduled for Tuesday 10-August at 11am (ET) and plans to provide an update on its financials and a progress update on the two ongoing pivotal Phase 3 studies (MARINE and ANCHOR) for AMR101 as a purified, prescription-grade omega-3 fatty acid compound that is being evaluated for the treatment of high triglycerides. Complete Story » seekingalpha.com |
Array Biopharma: A Wall Street Anomaly Ohad Hammer submits:Array’s (ARRY) shares keep on fluctuating in the $2.5-$3.5 range, relatively unchanged from the beginning of 2010. It seems that the market is having trouble assessing the real value of the company and its pipeline, which includes 13 (!) drugs in clinical trials. With a market cap of ~$170M, the market puts an average price tag of $13M per asset, a ridiculously low valuation (assuming no value is assigned to the company’s discovery platform). The company’s long term debt (due in 2014) could be partially blamed for this anomaly, but the problem seems to be more related to the company’s business model. The good news is that during the next year the company is looking at multiple events that might change the way Wall Street views Array.Array’s strength is also its Achilles’ heel: It has too many things going on and the majority of the programs are in early stage development without a clear and fast route to market. In that sense, the situation is very similar to that of Exelixis (EXEL), as I discussed two months ago. In order to get a realistic price tag from Wall Street, both companies must come up with a “killer app”, an indication that represents high probability of success, short time to market and a commercial opportunity of at least $100M. Although Array is not there yet, it could become highly attractive due to three trends: Out- licensing of wholly owned agents, maturation of partnered and proprietary programs and attrition.Maturing pipelineComplete Story » seekingalpha.com |
Lancôme Hosts Genes Day on 10/22 - Video Lancôme Declares October 22 Genes Day feedproxy.google.com |